#ClinicalTrial EAQ221CD/CONCURxP, led by @GelarehSadigh of @UCIrvineHealth, aims to find out if mobile reminders can help #BreastCancer patients follow the medication schedule that their doctor ordered. https://bit.ly/EAQ221CD
Kudos to @NorthwesternMed Lake Forest Hospital for
enrolling their first patient in #ClinicalTrial EA5182. This study explores AZD9291 (osimertinib) with or without bevacizumab as initial treatment for patients with EGFR-mutant #LungCancer. https://bit.ly/ea5182
#ClinicalTrial EAA173/DETER-SMM, led by @nsc_natalie of @UWCarbone, is a randomized phase 3 trial for patients with smoldering #MultipleMyeloma (#SMM) and high-risk features. Learn more here: https://bit.ly/eaa173detersmm #mmsm #BloodCancer
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
Active Clinical Trials
Participating Institutions
International Sites
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).